Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma.
Adenocarcinoma of Lung
/ genetics
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Carcinoma, Squamous Cell
/ genetics
Combined Modality Therapy
Female
Follow-Up Studies
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms
/ genetics
Lymphatic Metastasis
Male
Middle Aged
Peritoneal Neoplasms
/ genetics
Prognosis
Retrospective Studies
Survival Rate
Massively-parallel sequencing
Molecular pathology
NSCLC
Non-small cell lung carcinoma
Peritoneal carcinomatosis
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
06
2019
accepted:
06
08
2019
pubmed:
14
8
2019
medline:
13
7
2021
entrez:
14
8
2019
Statut:
ppublish
Résumé
To retrospectively characterize the molecular features of Non-Small Cell Lung Carcinomas (NSCLC) with peritoneal carcinomatosis (PC), clinicopathological data of 12 patients diagnosed with NSCLC and PC between 2007 and 2016 were collected. Immunohistochemistry and Next Generation Sequencing (NGS) were performed on cases with available material. PC was the initial presentation of NSCLC in 17% of the cases. Overall, patients with PC displayed a poor median survival of 12 weeks. Histology was adenocarcinoma in 11 cases. 37.5% of cases showed PD-L1 immunostaining positivity (50% cut-off). ALK and ROS1 immunostainings were negative. Using NGS, we identified 17 molecular alterations in 9 genes (TP53, KRAS, STK11, BRAF, EGFR, DDR2, ERBB4, SMAD4, CTNNB1) in 88.9% of adenocarcinomas. To the best of our knowledge, 5 of these variants are not referenced in the literature. In conclusion, PC might be the initial presentation of NSCLC. Molecular profiling of our cases did not find any effective targetable alteration, except from high PD-L1 expression.
Identifiants
pubmed: 31407221
doi: 10.1007/s12253-019-00713-1
pii: 10.1007/s12253-019-00713-1
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2795-2800Références
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386
doi: 10.1002/ijc.29210
Satoh H, Ishikawa H, Yamashita YT, Kurishima K, Ohtsuka M, Sekizawa K (2001) Peritoneal carcinomatosis in lung cancer patients. Oncol Rep 8(6):1305–1307
pubmed: 11605054
Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC (2016) Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer 96:27–32
doi: 10.1016/j.lungcan.2016.03.007
Sereno M, Rodríguez-Esteban I, Gómez-Raposo C, Merino M, López-Gómez M, Zambrana F et al (2013) Lung cancer and peritoneal carcinomatosis. Oncol Lett 6(3):705–708
doi: 10.3892/ol.2013.1468
Su H-T, Tsai C-M, Perng R-P (2008) Peritoneal carcinomatosis in lung cancer. Respirol 13(3):465–467
doi: 10.1111/j.1440-1843.2008.01268.x
McNeill PM, Wagman LD, Neifeld JP (1987) Small bowel metastases from primary carcinoma of the lung. Cancer 59(8):1486–1489
doi: 10.1002/1097-0142(19870415)59:8<1486::AID-CNCR2820590815>3.0.CO;2-W
Okami J, Taniguchi K, Higashiyama M, Maeda J, Oda K, Orita N, Koizumi K, Kodama K, Kato K (2007) Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. Oncology 72(3–4):234–242
doi: 10.1159/000112947
Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS (2016) Examining treatment outcomes with Erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol 11(4):545–555
doi: 10.1016/j.jtho.2015.12.107
Shajani-Yi Z, de Abreu FB, Peterson JD, Tsongalis GJ (2018) Frequency of somatic TP53 mutations in combination with known pathogenic mutations in colon adenocarcinoma, non-small cell lung carcinoma, and gliomas as identified by next-generation sequencing. Neoplasia 20(3):256–262
doi: 10.1016/j.neo.2017.12.005
Marte B (2013) Tumour heterogeneity. Nature 501:327
doi: 10.1038/501327a
Bhattacharya S, Socinski MA, Burns TF (2015) KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. Clin Transl Med 4(1):35
doi: 10.1186/s40169-015-0075-0
Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S et al (2017) Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget 9(5):6630–6643
pubmed: 29464099
pmcid: 5814239
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075
doi: 10.1038/nature07423
Pécuchet N, Laurent-Puig P, Mansuet-Lupo A, Legras A, Alifano M, Pallier K et al (2017) Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget 8(14):23831–23840
doi: 10.18632/oncotarget.6379
Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T et al (2017) Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Br J Cancer 117(10):1450–1458
doi: 10.1038/bjc.2017.308
Carter J, Tseng L-H, Zheng G, Dudley J, Illei P, Gocke CD, Eshleman JR, Lin MT (2015) Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool. Am J Clin Pathol 144(4):620–628
doi: 10.1309/AJCP85ATMJOZOUDJ
Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2):209–221
doi: 10.1016/j.cell.2009.12.040
Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543–550
doi: 10.1038/nature13385